ClinicalTrials.gg
RecruitingNCT07509658TriClip JP PASUpdated Apr 3, 2026

TriClip Japan Post-Approval Study

An observational study in Tricuspid Regurgitation, sponsored by Abbott Medical Devices. Recruiting at 1 site in Japan. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by Abbott Medical Devices (part of Abbott) · Observational

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
250
Sex
All
01

Study summary

The goal of this observational post approval study is to confirm the safety and efficacy of the TriClip System when used in routine clinical practice in the Japanese population and to fulfill post-market requirements following commercial approval in Japan.

Read the detailed description

Tricuspid Regurgitation (TR) is an abnormal condition which has both short-term and long-term consequences. TR decreases forward cardiac output and raises right-sided systemic venous pressures. This physiology will often result in hepatorenal congestion and dysfunction and, in addition, cause edema and ascites. The retrograde cardiac blood flow and volume loading also leads to further tricuspid dilatation exacerbating regurgitation over time.

The TriClip System is indicated for TR reduction in patients with symptomatic severe tricuspid regurgitation despite optimal medical therapy, who are under the following conditions, as determined by a heart team:

  • Patients with left-sided disease must be well treated according to the Japan guideline
  • Patients for whom tricuspid valve surgery is not the optimal treatment
  • Patients in whom transcatheter edge-to-edge valve repair is clinically appropriate

The objective of the TriClip Japan post-approval study is to confirm the safety and efficacy of the TriClip System for the treatment of symptomatic severe tricuspid regurgitation in a contemporary, real-world setting in the Japanese population, using the commercially available device in accordance with its approved indications for use.

02

Conditions studied

  • Tricuspid Regurgitation

Keywords

  • TR
  • Tricuspid Regurgitation
  • TriClip
03

In context

Tricuspid Valve Insufficiency

228 studies on the registry are indexed under Tricuspid Valve Insufficiency; 110 are open to participants now.

This study's planned enrollment of 250 is above the median of 200 across 95 observational studies indexed under Tricuspid Valve Insufficiency.

Browse Tricuspid Valve Insufficiency studies →

Lead sponsor

Abbott Medical Devices is the lead sponsor of 540 studies on the registry; 34 are open to participants now.

Of its 53 completed or terminated interventional studies of FDA-regulated products, 44 (83%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

This observational post-approval study will enroll subjects from the general Japanese population who are scheduled to undergo the TriClip procedure per the current Japan IFU.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects are eligible to receive the TriClip System per the current approved indications for use (IFU)
  • Subjects provide written prior to conducting any investigation-specific procedures not considered standard of care.

Exclusion criteria

Exclusion Criteria:

  • There are no exclusion criteria
  • Please note: It is not recommended that subjects enrolled in the study participate in any other therapeutic clinical study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
250 participants (estimated)
Patient registry
No

Groups and cohorts

  • Subjects who receive TriClip procedure with TriClip System

    The subjects from the general Japanese population are scheduled to undergo the TriClip procedure with commercially approved TriClip System per the current Japan Indication for Use (IFU).

    Device: The TriClip System

Interventions

  • DeviceThe TriClip System

    The TriClip System procedure will be performed in accordance with the Indication for Use (IFU) in Japan. The TriClip System is a transcatheter tricuspid valve repair system used to facilitate transcatheter edge-to-edge repair of the tricuspid valve leaflets and designed to deliver and deploy the Clip

06

What researchers measure

Primary outcomes

  1. Moderate or less Tricuspid Regurgitation (TR) at 30-day visit

    TR grade, defined as the proportion of subjects with TR severity classified as moderate or less, will be evaluated at the 30-day follow-up visit

    Time frame: 30 days

  2. Single Leaflet Device Attachment (SLDA) at 30-day visit

    SLDA rate, defined as the proportion of subjects with SLDA, will be evaluated at 30-day follow-up visit

    Time frame: 30 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Feb 2027, 11 months after the start.

Of 47 observational studies under Tricuspid Valve Insufficiency, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 106. This study's planned 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2026
First posted
Apr 3, 2026
StartActual
Mar 2, 2026
Primary completionEst.
Feb 28, 2027
CompletionEst.
Dec 15, 2029
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07509658
Responsible party
Sponsor
First posted
Apr 3, 2026
Start date
Mar 2, 2026
Primary completion
Feb 28, 2027 (estimated)
Completion
Dec 15, 2029 (estimated)
Last update
Apr 3, 2026

Study contacts

Jacob Zbinden
Contact
jacob.zbinden@abbott.com
+16517564272
Meghan Griffin
Contact
meghan.griffin@abbott.com

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion